BPC-157 has demonstrated broad beneficial effects across preclinical models (tissue injury, inflammatory bowel disease, and central nervous system disorders), giving rise to its reputation as a multi-system repair compound, according to a review published in Pharmaceuticals
Food and Drug Administration (FDA) - "Saxenda (Liraglutide) Injection, for Subcutaneous Use." Accessed on April 3, 2024, at FDA - "Drug Compounding and Drug Shortages." Accessed on April 3, 2024, at Harvard T.H
These patients often have fluctuating hormone levels rather than the flat postmenopausal profile, which makes fixed-dose commercial products a less precise fit
GLP-1 is a gut hormone that the body naturally releases after eating to help reduce blood sugar levels
Animal studies have demonstrated that FOXO4-DRI can reduce senescent cell burden, improve tissue function, and mitigate age-related pathologies [3] [4] [5]